Value of FLT PET/CT in Radium-223 Therapy of mCRPC Patients

Rigshospitalet

Status: Terminated

Conditions: Metastatic Prostate Carcinoma

Treatments: Other: FLT PET/CT

Study type: Interventional

Funder types: Other

Identifiers

NCT03011749

H1603551

Details and patient eligibility

About

The aim of the study is to investigate whether positron emission tomography (PET) using the tracer 18F-Fluorothymidine (FLT) can provide information on proliferative activity in bone marrow of patients receiving Radium 223 therapy and potentially be a predictive marker of hematological toxicity

Enrollment: 6 patients

Sex: Male

Volunteers: No Healthy Volunteers

Inclusion criteria

• Metastatic castration resistant prostate cancer
• Eligible for Radium-223 therapy
• Informed consent

Exclusion criteria

• Inability to understand study protocol
• Extensive metastatic involvement of the axial skeleton ("superscan" on bone scintigraphy)

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

6 participants in 1 patient group

FLT PET/CT

Experimental group

Description:

FLT PET/CT

Treatment:

Other: FLT PET/CT